Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation.
Identifying the antigens that have the potential to trigger endogenous antitumor responses in an individual cancer patient is likely to enhance the efficacy of cancer immunotherapy, but current methodologies do not efficiently identify such antigens. This study describes what we believe to be a new method of comprehensively identifying candidate tissue antigens that spontaneously cause T cell responses in disease situations. We used the newly developed automated, two-dimensional chromatography system PF2D to fractionate the proteome of human tumor tissues and tested protein fractions for recognition by preexisting tumor-specific CD4+ Th cells and CTLs. Applying this method using mice transgenic for a TCR that recognizes an OVA peptide presented by MHC class I, we demonstrated efficient separation, processing, and cross-presentation to CD8+ T cells by DCs of OVA expressed by the OVA-transfected mouse lymphoma RMA-OVA. Applying this method to human tumor tissues, we identified MUC1 and EGFR as tumor-associated antigens selectively recognized by T cells in patients with head and neck cancer. Finally, in an exemplary patient with a malignant brain tumor, we detected CD4+ and CD8+ T cell responses against two novel antigens, transthyretin and calgranulin B/S100A9, which were expressed in tumor and endothelial cells. The immunogenicity of these antigens was confirmed in 4 of 10 other brain tumor patients. This fast and inexpensive method therefore appears suitable for identifying candidate T cell antigens in various disease situations, such as autoimmune and malignant diseases, without being restricted to expression by a certain cell type or HLA allele.
Beckhove
Philipp
P
Translational Immunology Unit, German Cancer Research Center, Heidelberg, Germany.
Warta
Rolf
R
Lemke
Britt
B
Stoycheva
Diana
D
Momburg
Frank
F
Schnölzer
Martina
M
Warnken
Uwe
U
Schmitz-Winnenthal
Hubertus
H
Ahmadi
Rezvan
R
Dyckhoff
Gerhard
G
Bucur
Mariana
M
Jünger
Simone
S
Schueler
Thomas
T
Lennerz
Volker
V
Woelfel
Thomas
T
Unterberg
Andreas
A
Herold-Mende
Christel
C
D000818:Animals; D000941:Antigens / Q000276:immunology / Q000378:metabolism; D000951:Antigens, Neoplasm / Q000737:chemistry* / Q000276:immunology* / Q000378:metabolism; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D045142:Cross-Priming / Q000276:immunology; D006680:HLA Antigens / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D051379:Mice; D008810:Mice, Inbred C57BL; D009369:Neoplasms / Q000276:immunology / Q000378:metabolism; D010455:Peptides / Q000737:chemistry* / Q000276:immunology* / Q000378:metabolism; D011506:Proteins / Q000276:immunology / Q000378:metabolism; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology* / Q000378:metabolism; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000378:metabolism
D000941:Antigens; D000951:Antigens, Neoplasm; D006680:HLA Antigens; D010455:Peptides; D011506:Proteins
J Ind Microbiol Biotechnol. 2006 Nov;33(11):914-20
16964509
Proteomics. 2005 Jul;5(10):2641-7
15912557
J Neurosci Methods. 2007 Apr 15;161(2):250-8
17207861
Cancer Immunol Immunother. 2005 Mar;54(3):187-207
15309328
Cancer Res. 2004 Dec 15;64(24):9018-26
15604267
Biochemistry. 1978 Dec 26;17(26):5729-33
728432
Arch Pharm Res. 2007 Jan;30(1):75-81
17328245
Cancer Res. 2002 Oct 15;62(20):5818-27
12384544
Mol Immunol. 1994 Dec;31(18):1423-30
7823968
DNA Cell Biol. 2002 Jan;21(1):11-9
11879576
Eur J Immunol. 2000 Aug;30(8):2216-25
10940913
Science. 1994 Apr 29;264(5159):716-9
7513441
J Clin Invest. 2009 Nov;119(11):3311-21
19809157
Cancer. 2008 Mar 15;112(6):1313-24
18257091
Mol Cell Proteomics. 2006 Jan;5(1):26-34
16188874
Mol Cell Proteomics. 2006 Jan;5(1):35-42
15951525
Cancer Res. 2006 Aug 15;66(16):8258-65
16912206
Proteomics. 2008 Jun;8(11):2168-77
18528841
Anal Biochem. 2006 Dec 1;359(1):84-93
17034751
Anal Chim Acta. 2008 Oct 3;627(1):71-81
18790129
J Biol Chem. 2001 Jan 12;276(2):1107-13
11036082
APMIS. 1996 Feb;104(2):115-25
8619913
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16013-8
16247014
Clin Cancer Res. 2009 Sep 1;15(17):5323-37
19723653
Histopathology. 2005 Mar;46(3):256-69
15720411
Blood. 2005 Mar 1;105(5):2132-4
15561890
Nat Med. 2001 Apr;7(4):452-8
11283672
J Biol Chem. 1971 Jan 10;246(1):44-9
5541771
Lab Invest. 1999 Dec;79(12):1573-82
10616207
Cancer Res. 2002 Dec 1;62(23):6823-6
12460893
J Proteome Res. 2007 Jun;6(6):2168-75
17488104
Cancer Biol Ther. 2005 Sep;4(9):943-8
16082191
J Immunother. 2009 Jan;32(1):92-9
19307998
FEBS J. 2007 Apr;274(7):1637-50
17381508
J Immunol. 1995 Nov 15;155(10):4676-84
7594467
Int J Cancer. 1989 Jun 15;43(6):1072-6
2471698
Immunogenetics. 1999 Nov;50(3-4):213-9
10602881
Tissue Antigens. 2007 Oct;70(4):319-23
17767554
Int Immunol. 2003 Jun;15(6):751-63
12750359
J Neurooncol. 2009 Aug;94(1):31-9
19219580
J Immunol. 1998 Feb 1;160(3):1427-35
9570563
C R Biol. 2003 Oct-Nov;326(10-11):1067-72
14744114
J Immunother. 2010 Jan;33(1):83-91
19952953
Anticancer Res. 2003 May-Jun;23(3A):2043-51
12894577
Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3
8524854
Annu Rev Immunol. 1996;14:333-67
8717518
Cancer Res. 2006 Jun 15;66(12):5997-6001
16778169
Eur J Immunol. 1994 Sep;24(9):2068-72
8088327